Loading...
•
Dec 31, 2024
Solventum Q4 2024 Earnings Report
Solventum reported steady sales growth in Q4 2024, with notable improvements in operating income and free cash flow.
Key Takeaways
Solventum delivered a solid quarter with total sales reaching $2.074 billion, marking a 1.9% increase year-over-year. GAAP diluted EPS stood at $0.17, while adjusted EPS reached $1.41. The company generated $219 million in operating cash flow and achieved $92 million in free cash flow. Organic sales growth was led by MedSurg and Dental Solutions segments.
Total sales increased 1.9% YoY to $2.074 billion.
GAAP EPS was $0.17, while adjusted EPS reached $1.41.
Operating income stood at $136 million GAAP and $422 million adjusted.
Free cash flow for the quarter was $92 million.
Solventum
Solventum
Solventum Revenue by Segment
Revenue by Segment
MedSurg Revenue
CapyFin.comDental Solutions Revenue
CapyFin.comHealth Info Systems Revenue
CapyFin.comPurification & Filtration Revenue
CapyFin.com Forward Guidance
Solventum anticipates continued moderate sales growth in 2025, with stable earnings and strong free cash flow generation.
Positive Outlook
- Organic sales growth expected between 1.0% and 2.0%.
- Adjusted EPS projected between $5.45 and $5.65.
- Free cash flow guidance set at $450M to $550M.
- Continued strong performance in MedSurg and Dental Solutions.
- Strategic cost management efforts to sustain margins.
Challenges Ahead
- Potential impact from SKU exit reducing growth by 0.5%.
- Macroeconomic headwinds could impact demand.
- Operational expenses may remain elevated due to transition costs.
- Uncertainty surrounding Purification & Filtration segment sale.
- Currency fluctuations may impact international revenue.
Revenue & Expenses
Visualization of income flow from segment revenue to net income